|
⚲
|
| Keyboard |
| SR One Capital Management LP
✚
|
|
|---|---|
| CRD # | 306361 |
| SEC # | 801-119142 |
| CIK # | 0001910264, 0001853723 |
| AUM | 2,435.9 M (2026-03-31) |
| Employees | 28 (54% Investors, 0% Brokers) |
| Phone | 408-303-2673 |
| Address | 929 Main Street Redwood City, CA 94063 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Veradermics Inc | 151.7 | ||
| Zenas Biopharma Inc | 98.5 | ||
| CRISPR Therapeutics AG | 97.0 | ||
| Design Therapeutics Inc | 69.4 | ||
| Oric Pharmaceuticals Inc | 58.5 | ||
| Alumis Inc | 43.2 | ||
| Mineralys Therapeutics Inc | 42.4 | ||
| Silverback Therapeutics Inc | 32.2 | ||
| ARCA Biopharma Inc | 21.1 | ||
| Oculis Holding AG | 17.0 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | SR One Co-Invest XIII LLC | [2026-03-31] | 15.4 M | |
| Filed 2025-08-04 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Synapse Investment LP | [2026-03-31] | 105.3 M | |
| Filed 2025-09-09 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | SR One Capital Fund III LP | [2025-03-31] | 237.1 M | 236.1 M |
| Offered $600,000,000 · Filed 2025-10-09 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $362,868,686 · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | AMZL LP | [2024-03-28] | 573.5 M | |
| Filed 2023-04-04 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | SR One Capital Opportunities Fund I LP | [2024-03-28] | 236.6 M | |
| Filed 2023-04-04 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | SR One Co-Invest Xi LLC | [2023-03-31] | 18.2 M | |
| Filed 2022-09-23 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | SR One Co-Invest IV-A LLC | [2022-06-14] | 7.8 M | |
| Filed 2022-05-12 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | SR One Co-Invest IX LLC | [2022-06-14] | 1.3 M | |
| Filed 2022-04-25 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | SR One Co-Invest XII LLC | [2022-06-14] | 1.2 M | |
| Filed 2022-05-12 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | SR One Co-Invest X LLC | [2022-06-14] | 1.3 M | |
| Filed 2022-04-25 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 19 | 2.4 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 19 | 2.4 |
| By Discretionary | ||
| Discretionary | 19 | 2.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 19 | 2.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.8 | |
| United States Persons | 1.7 | |
| Total | 19 | 2.4 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Richard Thoms | Executive Officer | 7187 | 139 | |
| Assure Fund Management II | Director | 6187 | 139 | |
| Jeremy Neilson | Executive Officer | 6656 | 98 | |
| Rajeev Dadoo | Executive Officer | 20 | 2 | |
| Matthew Foy | Executive Officer | 9 | 2 | |
| SR One Capital Partners III LP | Executive Officer | 1 | 1 | |
| Synapse Investment Partners I LP | Executive Officer | 1 | 1 | |
| SR One Capital Partners III LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001853723] | |
| 4 | [0001853723] | |
| SC 13D | [0001853723] | |
| SC 13G | [0001853723] | |
| 13F-HR | [0001910264] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Private Equity |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Zenas BioPharma Inc ZBIO
Common Stock
|
2025-10-09 | Buy | 63,157 | $19.00 | 1,199,983 |
|
Zenas BioPharma Inc ZBIO
Common Stock
|
2025-10-09 | Buy | 63,158 | $19.00 | 1,200,002 |
|
Zenas BioPharma Inc ZBIO
Common Stock
|
2024-09-16 | Buy | 441,176 | $17.00 | 7,499,992 |
|
Zenas BioPharma Inc ZBIO
Common Stock
|
2024-09-16 | Conversion | 1,505,388 | ||
|
Zenas BioPharma Inc ZBIO
Common Stock
|
2024-09-16 | Buy | 1,352,942 | $17.00 | 23,000,014 |
|
Zenas BioPharma Inc ZBIO
Common Stock
|
2024-09-16 | Conversion | 501,796 | ||
|
Zenas BioPharma Inc ZBIO
Series C Convertible Preferred Stock · derivative
|
2024-09-16 | Conversion | 5,809,528 | ||
|
Zenas BioPharma Inc ZBIO
Series C Convertible Preferred Stock · derivative
|
2024-09-16 | Conversion | 4,357,146 | ||
|
Zenas BioPharma Inc ZBIO
Series C Convertible Preferred Stock · derivative
|
2024-09-16 | Conversion | 13,071,439 | ||
|
Zenas BioPharma Inc ZBIO
Common Stock
|
2024-09-16 | Buy | 441,176 | $17.00 | 7,499,992 |
|
Zenas BioPharma Inc ZBIO
Common Stock
|
2024-09-16 | Conversion | 669,061 | ||
|
eFFECTOR Therapeutics Inc EFTR
Common Stock
|
2023-11-27 | Sell | 178,585 | $0.61 | 108,937 |
|
eFFECTOR Therapeutics Inc EFTR
Common Stock
|
2023-11-27 | Sell | 430,578 | $0.61 | 262,653 |
|
Arcellx Inc ACLX
Common Stock
|
2023-05-11 | Sell | 3,804 | $46.15 | 175,555 |
|
Arcellx Inc ACLX
Common Stock
|
2023-05-11 | Sell | 6,485 | $46.15 | 299,283 |
|
Arcellx Inc ACLX
Common Stock
|
2023-05-11 | Sell | 631,932 | $45.00 | 28,436,940 |
|
Arcellx Inc ACLX
Common Stock
|
2023-05-11 | Sell | 370,612 | $45.00 | 16,677,540 |
|
Design Therapeutics Inc DSGN
Common Stock
|
2022-12-20 | Buy | 40,000 | $8.14 | 325,600 |
|
Design Therapeutics Inc DSGN
Common Stock
|
2022-12-19 | Buy | 360,000 | $8.63 | 3,106,800 |
|
Design Therapeutics Inc DSGN
Common Stock
|
2022-12-16 | Buy | 500,000 | $8.28 | 4,140,000 |
| showing 20 of 37 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Align Ventures Special Opportunity GP SPV I LLC
✚
|
2,464.7 M | |
|
Martis Capital Management LLC
✚
|
DC | 2,459.4 M |
|
Forge Global Advisors LLC
✚
|
CA | 2,458.6 M |
|
Unigestion US Ltd
✚
|
NY | 2,453.9 M |
|
Balance Point Capital Advisors LLC
✚
|
CT | 2,442.1 M |
|
Crayhill Capital Management LP
✚
|
NY | 2,440.0 M |
|
BlackRock Asset Management Schweiz AG
✚
|
2,434.3 M | |
|
Paceline Equity Partners LLC
✚
|
TX | 2,427.3 M |
|
Valeas Capital Partners Management LP
✚
|
CA | 2,425.8 M |
|
Align Capital Partners LP
✚
|
OH | 2,408.3 M |